Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gedivumab - Genentech

Next Previous
Drug Profile

Gedivumab - Genentech

Alternative Names: Gedivumab; MHAA-4549A; RG 7745; RO 6876802

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Influenza A virus infections

Most Recent Events

  • 30 Jan 2020 Discontinued - Phase-II for Influenza A virus infections (Combination therapy) in Mexico, Taiwan, Russia, Sweden, Italy, Peru, Netherlands, Israel, South Africa, Ukraine, Spain, Poland, New Zealand, Hungary, Hong Kong, France, Chile, Bulgaria, Brazil, Germany, Czech Republic, Belgium, Canada, United Kingdom (IV) before January 2020
  • 30 Jan 2020 Discontinued - Phase-II for Influenza A virus infections (Monotherapy) in New Zealand, South Korea, South Africa, Spain, United Kingdom, Canada, USA (IV) before January 2020
  • 21 Apr 2018 Efficacy and adverse events data from a phase IIb trial in Influenza-A virus infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top